Event date: 14 October 2021
About the event
As someone pursuing the clinical promise of a biotherapeutic molecule, you already believe in the technology’s potential. Cytiva believes scientists from Australia and New Zealand have many biotherapeutic molecules of promise trapped on the bench. Cytiva wants to enable these molecules to make the jump from the bench to the clinic. So, they have launched the ANZ BioChallenge.
In this webinar Cytiva has collaborated with the BioMelbourne Network to offer insights into their current support program. The program is unique to Cytiva ANZ.
Applications are available to any organisation in Australia and New Zealand who have a biologic molecule that needs a boost in one of three (3) focus areas: cell engineering, process development, and isolation and purification. With AU$360,000 worth of awards to be won it is well worth finding out more.
Speakers (more info below)
Event details
- Date (AEDT): 14 October 2021
- Time (AEDT): 4pm – 4:50pm
- Format: Online via Zoom Webinar | Presentation of information | Discussion of FAQ’s | Audience Q&A
- Speakers: Tim O’Meara, Stephen O’Sullivan and Edwin Huang
- Panellist: Janelle Bryce, Marketing Manager ANZ, Cytiva
- Host and Facilitator: Dr Elane Zelcer, Deputy Chair, BioMelbourne Network
This is a free event. Register below.
This BioMelbourne Network event is delivered in collaboration with Cytiva.
Tim’s role at Cytiva is to work with governments, industry and academia to support bio-pharmaceutical research and biotechnology companies in Australia and New Zealand. He currently also has an Adjunct appointment at UTS. Tim has had around 21 steps in his career, so far, from graduate economist in Canberra, PhD in immunology, biochemistry lecturer, asthma researcher, entrepreneur, environmental health consultant, several business development and leadership roles in CSIRO and Regional Research Manager for GE Healthcare's Global Research Organisation.
Stephen has over 14 years’ experience in the Life Sciences industry and for the past 5 years has been working directly with start-up biotech and biopharmaceutical manufacturing companies to achieve their goals. He has an extensive knowledge of bioprocess workflows, facilities design and technology solution for both mammalian and bacterial expressions platforms. The Enterprise solution team specialises in building end to end biomanufacturing process and facilities to support the manufacture of advance therapeutics. Stephen has also lead projects with Cytiva’s FastTrak (CDMO) service team, recently working closely with the University of Queensland’s rapid response vaccine team to accelerate the program by supporting advanced development of new purification technologies.
Edwin has over 15 years of research and commercial experience in bio-processing technology, covering microbial, plant cell and mammalian cell systems for various bio-production purposes, with a strong focus in mammalian application for biologics production to support pre- to early stage of clinical studies.
Edwin has held various technical and managerial positions with local and oversea, private and publicly-listed start-ups, like Acyte (Sydney), Apollo Life Sciences (ASX:AOP), Biosceptre International (UK), and brought therapeutic antibody products into first in human use.
A cross discipline background in engineering, life science and commerce has enabled Edwin to provide sound business and investment consulting in areas of biopharmaceutical and life science to management, existing and prospective investors and other research firms.
Dr Elane Zelcer, Director, BioConsult Pty Ltd – joined BioMelbourne Network’s Board on 14 November 2019.
Dr Zelcer’s career spans academic, executive management, director, and management consulting roles, almost exclusively focused on life sciences and medical technologies. Her experience includes private sector (SME & multinational companies), universities, CRCs, and Federal and State government committees.
She has more than 20 years’ experience advising and assisting more than 120 companies, university spin-outs and research teams with strategic decision-making and risk management, governance, as well as strategic guidance for capital raising and commercialisation. Much of this activity has involved the intersection between the research sector and business.
She continues to use her knowledge and skills to assist start-up/early stage companies, and research based organisations to develop novel, value-add products in life sciences, healthcare and related sectors.
Janelle is the Marketing Manager ANZ for Cytiva - an organisation of more than 6700 people across 40 countries. With over 25 years’ experience in life sciences, biotech and biopharmaceuticals, Janelle is passionate about bringing transformative healthcare to patients through researchers, hospitals and the biopharmaceutical partners of Cytiva.
